Detalhe da pesquisa
1.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell
; 184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730597
2.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell
; 184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852911
3.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell
; 184(16): 4220-4236.e13, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242578
4.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Cell
; 184(8): 2201-2211.e7, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743891
5.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet
; 399(10342): 2212-2225, 2022 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691324
6.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883053
7.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
8.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
9.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
10.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370971
11.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
12.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
13.
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
J Infect Dis
; 223(7): 1171-1182, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821493
14.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
15.
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).
J Infect Dis
; 222(Suppl 7): S658-S665, 2020 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32794560
16.
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Clin Infect Dis
; 68(7): 1213-1222, 2019 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30759183
17.
Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood.
Proc Natl Acad Sci U S A
; 113(7): 1853-8, 2016 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755593
18.
No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
J Allergy Clin Immunol
; 137(6): 1772-1779.e11, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825000
19.
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
JAMA
; 315(15): 1610-23, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092831
20.
BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines.
Immunol Cell Biol
; 93(10): 885-95, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25976772